Routine Cardiac Screening in Sarcoidosis Patients
Key facts
- Who runs it
- Foundation for Sarcoidosis Research
- Where
- Albany, Charleston, Chicago, Cincinnati, Cleveland, Denver, Iowa City, Philadelphia, and Seattle, United StatesSee the 10 sitesAlso in 2 other countries, 2 sites
- Trial code
- Status
- Completed
- People taking part
- 1,000 people enrolled
- Started
- 5 Apr 2019
- Ended
- 1 Nov 2024
- Type of study
- Observational, 2 groups
- Treatments tested
- Enhanced Screening Protocol for Cardiac Sarcoidosis.
- Routine Screening for Suspected Cardiac Sarcoidosis
- Record updated
- 14 January 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Diagnosis of sarcoidosis as per The American Thoracic Society guidelines
- First visit to the enrolling center
- Intent to continue care at the enrolling center at least annually
Who cannot take part
- Referred to the enrolling center to evaluate for suspected cardiac sarcoidosis
- Pre-existing high suspicion for cardiac sarcoidosis, defined as having had cardiac MRI or cardiac PET scan, even if it was ordered by other institutions
- Severe sarcoidosis or other disease conferring a high likelihood of death or transplant within the next year
- Unwilling or unable to undergo echocardiography and ambulatory ECG
Where in United States
Also in 2 other countries, 2 sites
- Albany Medical CenterAlbany, United States
- Medical University of South CarolinaCharleston, United States
- Northwestern University MedicineChicago, United States
- University of Illinois Medical Center at ChicagoChicago, United States
- University of Cincinnati Medical CenterCincinnati, United States
- Cleveland ClinicCleveland, United States
- National Jewish HealthDenver, United States
- University of Iowa HospitalIowa City, United States
- Penn MedicinePhiladelphia, United States
- University of Washington Medical CenterSeattle, United States
About the trial
What the trial wants to find out
This protocol is an unblended randomized screening trial will have consecutive patients with no suggestion of cardiac sarcoidosis according to usual screening enroll in an enhanced screening protocol. The routine clinical care is to gather patient's history of symptoms and under go an ECG. If a patient has an abnormal results in standard screening, they typically have further evaluations as part of their routine medical care. These tests might include an echocardiogram, ambulatory ECG, and advanced cardiac imaging (MRI, PET scan as per local practice). A patient that has normal results on standard screening will be randomly assigned to enhanced screening at each center. Half the patients will be randomized to usual follow-up (annual symptom assessment and ECG) and the other half will be assigned to the enhanced screening (echocardiogram and ambulatory ECG at enrollment and at 24 months).
Read full original descriptionShow less
The investigators hypothesize that screening using conventional history, physical and ECG in the general sarcoidosis population, followed by appropriate advanced imaging testing, will result in the identification of a higher percentage of ascertained cardiac sarcoidosis than has been reported historically (2-5%). The investigators hypothesize that routine use of echocardiogram with strain and ambulatory ECG will identify additional patients who will have advanced imaging abnormalities or who meet criteria for cardiac sarcoidosis. The investigators further hypothesize that re-screening patients after 24 months with repeat echocardiogram and ambulatory ECG will identify additional patients with suspicion for cardiac sarcoidosis who had no abnormalities on the standard screening tests.
The 2 groups in the trial
- Enhanced Screening Protocol For Cardiac Sarcoidosis
Arm will be randomly assigned to undergo enhanced screening methods (ambulatory ECG and echocardiogram) at month 0 and month 24, as well as a phone call/chart review at month 12.
- Routine Screening for Suspected Cardiac Sarcoidosis
Arm will be randomly assigned for the routine standard of care/no intervention with enhanced screening methods. They will be offered the EKG and symptom check at months 0 and 24, as well as a phone call/chart review at month 12.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomized Screening Trial for Cardiac Sarcoidosis (CS) in Patients Seen During Routine Clinical Care Who Have Not Been Clinically Suspected to Have (CS), Comparing the Addition of Echocardiogram and Ambulatory ECG to Standard of Care.
- Record updated
- 14 January 2025